Suvorexant
FDA-approved product (tablet, oral), marketed as Belsomra.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Orexin receptor antagonists
- FDA pharmacologic class
- Orexin Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pipecuronium BromideExisting use: Other quaternary ammonium compounds42.9% AI-predicted activityagainst K. pneumoniae5 registered studies
- Fosaprepitant DimeglumineExisting use: Cancer, Chemotherapy-induced nausea and vomiting, Nausea and 3 more42.9% AI-predicted activityagainst K. pneumoniae21 registered studies
- CabergolineExisting use: Hypothalamic neoplasm, Parkinson disease42.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more42.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder42.6% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vecuronium BromideExisting use: Other quaternary ammonium compounds42.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease42.0% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia41.9% AI-predicted activityagainst K. pneumoniae6 registered studies
- RepotrectinibExisting use: Cancer, Neoplasm41.8% AI-predicted activityagainst K. pneumoniae17 registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis41.7% AI-predicted activityagainst K. pneumoniae25 registered studies
- PralsetinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 1 more41.5% AI-predicted activityagainst K. pneumoniae19 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
NCT01293006 · start 2011-03-25
Registered record
- Registry ID
- NCT01293006
- Conditions
- Insomnia
- Interventions
- suvorexant; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-03-25
- Completion
- 2012-02-22
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionsuvorexant; PlaceboPhasePhase 1Registry statusCompletedPharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
NCT01059851 · start 2010-05-24
Registered record
- Registry ID
- NCT01059851
- Conditions
- Insomnia
- Interventions
- Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-05-24
- Completion
- 2010-07-15
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionSuvorexantPhasePhase 1Registry statusCompletedSafety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
NCT01097616 · start 2010-05-05
Registered record
- Registry ID
- NCT01097616
- Conditions
- Primary Insomnia
- Interventions
- Suvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-05-05
- Completion
- 2011-12-07
- Enrolment
- 1,023
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary InsomniaInterventionSuvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: PlaceboPhasePhase 3Registry statusCompletedA Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
NCT01021813 · start 2009-12-10
Registered record
- Registry ID
- NCT01021813
- Conditions
- Insomnia
- Interventions
- Suvorexant; Dose-matched Placebo to Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-12-10
- Completion
- 2011-08-01
- Enrolment
- 781
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionSuvorexant; Dose-matched Placebo to SuvorexantPhasePhase 3Registry statusCompletedPhase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
NCT00792298 · start 2008-11-05
Registered record
- Registry ID
- NCT00792298
- Conditions
- Primary Insomnia
- Interventions
- Suvorexant; Dose-matched Placebo to Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-11-05
- Completion
- 2009-12-26
- Enrolment
- 254
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary InsomniaInterventionSuvorexant; Dose-matched Placebo to SuvorexantPhasePhase 2Registry statusCompleted